Progranulin: A Novel Gene in Gaucher Diseases

颗粒体蛋白前体:戈谢病的一个新基因

基本信息

  • 批准号:
    10011889
  • 负责人:
  • 金额:
    $ 47.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-30 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Gaucher disease (GD) is a genetic disease caused by mutations in the GBA1 gene which result in reduced enzymatic activity of β-glucocerebrosidase (GCase); however, patients with the same GCase mutations may have significant variably in disease presentation, ranging from a life-threatening manifestation to almost asymptomatic. It is believed that the modifier genes are responsible for the extraordinarily diverse phenotypes among patients harboring identical GBA1 mutations. Thus, identification of new modifier genes in GD will provide invaluable information in understanding the pathogenesis of GD and in searching for novel diagnostic and therapeutic targets for GD. Our previous report that progranulin (PGRN) is therapeutic against inflammatory arthritis (Tang, et al. Science, 2011) prompted us to determine whether PGRN also played a role in lung inflammation using ovalbumin (OVA)-challenged asthma model, which led to the unexpected discovery of GRN (the gene encoding PGRN) as a novel gene in GD. PGRN null mice display typical features of GD, including “wrinkled tissue paper” appearance of Gaucher cells in multiple organs, and tubular-like lysosome transformation in macrophages. In addition, serum PGRN levels of GD patients are significantly lower when compared to healthy controls, and lower PGRN level was significantly associated with the GRN variants identified in GD patients (Jian, et al, EBioMedicine, 2016a). PGRN binds directly to GCase, and its deficiency results in aggregation in the cytoplasm and defects in the lysosomal localization of GCase. Additionally, 98 C- terminal amino acids of PGRN, referred to as Pcgin, are required and sufficient for the binding to GCase. Pcgin effectively ameliorates the disease phenotype in GD patient fibroblasts and OVA-challenged GD model (Jian, et al, EBioMedicine, 2016b). There is an urgent unmet medical need for treating neuropathic GD, since current enzyme replacement therapy for GD cannot penetrate into brain. Excitingly, our preliminary data revealed that Pcgin could cross blood brain barrier and might be also therapeutic against neuropathic GD. In an effort to elucidate the molecular mechanism underlying PGRN- and Pcgin-mediated therapeutic effect against GD, we performed an unbiased proteomics screen, which led to the isolation of protein disulfide-isomerase A3 (PDIA3) as a PGRN and Pcgin co-bound molecule. In addition, loss of PDIA3 abolished Pcgin's therapeutic effects in GD patient fibroblasts. The hypothesis of this application is that PGRN is a novel modifier in GD and its derivative Pcgin is therapeutic against GD. The Specific Aims are: (1) To determine the therapeutic role of PGRN and its derivative Pcgin in GD, in particular against neuropathic GD; and (2) To elucidate the cellular and molecular mechanisms by which PGRN and Pcgin regulate GCase and GD, with special focus on their interactions with PDIA3 in GD. Completion of the proposed research will not only present PGRN as a novel modifier of GD, provide new insight into the molecular events in the pathogenesis of GD, but could also lead to the development of novel biologics for treating GD, in particular neuropathic GD.
项目摘要 高谢病(GD)是一种由GBA1基因突变导致的遗传病 β-葡萄糖脑苷酶(GCase)的酶活性;然而,具有相同GCase突变的患者可能 有不同程度的疾病表现,从危及生命的表现到几乎 没有任何症状。人们认为修饰基因是导致异常不同的表型的原因。 在具有相同GBA1突变的患者中。因此,在GD Will中发现新的修饰基因 为了解GD的发病机制和寻找新的诊断方法提供了宝贵的信息 以及GD的治疗靶点。我们之前的报告中提到普罗布林(PGRN)可以治疗 炎症性关节炎(Tang,et al.科学,2011)促使我们确定PGRN是否也起到了作用 在肺部炎症中使用卵蛋白(OVA)激发哮喘模型,这导致了这一意想不到的发现 GRN(编码PGRN的基因)是GD中的一个新基因。PGRN基因缺失小鼠表现出典型的GD特征, 包括多器官内高雪氏细胞的“皱纹纸片”状外观,管状溶酶体 巨噬细胞的转化。此外,GD患者血清PGRN水平在以下情况下显著降低 与健康对照组相比,较低的PGRN水平与GRN变异显著相关 在GD患者中发现(Jian等人,EBioMedicine,2016a)。PGRN与GCase的直接结合及其缺陷 结果GCase在细胞质内聚集,在溶酶体定位上出现缺陷。此外,98℃- PGRN的末端氨基酸,称为Pcgin,是与GCase结合所必需的,也是足够的。加注 有效地改善GD患者成纤维细胞和OVA激发的GD模型的疾病表型(Jian, EBioMedicine等人,2016b)。治疗神经性GD有一个紧急的未得到满足的医疗需求,因为目前 酶替代疗法治疗GD不能透入大脑。令人兴奋的是,我们的初步数据显示 Pcgin可穿透血脑屏障,对神经性GD也有治疗作用。为了努力 阐明PGRN和Pcgin治疗GD的分子机制 进行蛋白质组学无偏筛选,分离出蛋白质二硫键异构酶A3(PDIA3) 作为PGRN和Pcgin共同结合的分子。此外,PDIA3的缺失取消了Pcgin的治疗作用 GD患者成纤维细胞。这一应用的假设是,PGRN是一种新的GD修饰物,其 其衍生物Pcgin对GD有治疗作用。具体目的是:(1)确定其治疗作用 PGRN及其衍生物Pcgin在GD中的作用,特别是对神经病理性GD的作用;以及(2)阐明细胞 以及PGRN和Pcgin调节GCase和GD的分子机制,尤其是它们的 与PDIA3在GD中的相互作用拟议研究的完成不仅将使PGRN成为一部小说 GD的修饰物,为了解GD发病机制中的分子事件提供了新的视角,但也可能导致 治疗GD,特别是神经病理性GD的新型生物制剂的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chuanju Liu其他文献

Chuanju Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chuanju Liu', 18)}}的其他基金

Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes
靶向 TNF 受体抑制炎症并促进 1 型糖尿病的骨再生
  • 批准号:
    10915157
  • 财政年份:
    2023
  • 资助金额:
    $ 47.91万
  • 项目类别:
The immunological mechanism of PGRNs anti-inflammatory effect
PGRNs抗炎作用的免疫学机制
  • 批准号:
    10912299
  • 财政年份:
    2023
  • 资助金额:
    $ 47.91万
  • 项目类别:
The Role of Sodium Channel Nav1.7 in Osteoarthritis - Resubmission - 1
钠通道 Nav1.7 在骨关节炎中的作用 - 重新提交 - 1
  • 批准号:
    10390155
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
A new mouse model to study GBA1 mutation-associated diseases with multiple organs involvement
研究GBA1突变相关多器官疾病的新小鼠模型
  • 批准号:
    10651885
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
A new mouse model to study GBA1 mutation-associated diseases with multiple organs involvement
研究GBA1突变相关多器官疾病的新小鼠模型
  • 批准号:
    10508985
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes - Resubmission - 1
靶向 TNF 受体抑制 1 型糖尿病炎症并促进骨再生 - 重新提交 - 1
  • 批准号:
    10453563
  • 财政年份:
    2020
  • 资助金额:
    $ 47.91万
  • 项目类别:
Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes - Resubmission - 1
靶向 TNF 受体抑制 1 型糖尿病炎症并促进骨再生 - 重新提交 - 1
  • 批准号:
    10218061
  • 财政年份:
    2020
  • 资助金额:
    $ 47.91万
  • 项目类别:
Progranulin: A Novel Gene in Gaucher Diseases
颗粒体蛋白前体:戈谢病的一个新基因
  • 批准号:
    10251862
  • 财政年份:
    2017
  • 资助金额:
    $ 47.91万
  • 项目类别:
Progranulin Intervention in Inflammatory Bowel Diseases
颗粒体蛋白前体干预炎症性肠病
  • 批准号:
    8708276
  • 财政年份:
    2013
  • 资助金额:
    $ 47.91万
  • 项目类别:
The Role of PGRN Growth Factor in Osteoarthritis
PGRN 生长因子在骨关节炎中的作用
  • 批准号:
    8698896
  • 财政年份:
    2013
  • 资助金额:
    $ 47.91万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 47.91万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 47.91万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 47.91万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 47.91万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 47.91万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 47.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了